New approaches to cancer chemoprevention with difluoromethylornithine and selenite.
New approaches to enhancing D,L-alpha-difluoromethylornithine (DFMO) inhibition of DMBA-induced mammary tumorigenesis were investigated. It is reasoned that perturbation of a second regulatory element in polyamine biosynthesis, i.e., the generation of propylamine groups from S-adenosylmethionine (AdoMet), would potentiate the effectiveness of DFMO. Precursor availability for AdoMet was limited when rats were fed a low methionine diet. The diet of control rats was supplemented with 0.3% methionine. DFMO, when added to the diet at 0.1%, suppressed tumorigenesis, regardless of methionine levels, although its efficacy was significantly enhanced by the low methionine diet. Selenite, another effective chemopreventive agent in this tumor model, also requires AdoMet for its metabolism. However, the anticarcinogenic action of selenite is not compromised by low dietary methionine. The differential sensitivity of DFMO and selenium chemoprevention to low dietary methionine, therefore, provides an opportunity to test for an additive effect. Results of the combination regimen study showed that the incidence and yield of DMBA-induced mammary tumors were significantly lower in the two-agent protocol compared to either DFMO or selenite alone. The mechanism(s) that accounts for the heightened efficacy of combined DFMO and selenite chemoprevention will be discussed.
Ip
C
C
Department of Breast Surgery, Roswell Park Memorial Institute, Buffalo, NY 14263.
Thompson
H J
HJ
D015127:9,10-Dimethyl-1,2-benzanthracene; D000230:Adenocarcinoma / Q000517:prevention & control*; D000818:Animals; D004032:Diet; D000518:Eflornithine / Q000627:therapeutic use*; D005260:Female; D008099:Liver / Q000201:enzymology; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D008715:Methionine / Q000008:administration & dosage*; D065108:Ornithine Decarboxylase Inhibitors; D051381:Rats; D011919:Rats, Inbred Strains; D020887:Selenious Acid; D012643:Selenium / Q000627:therapeutic use*
D065108:Ornithine Decarboxylase Inhibitors; D015127:9,10-Dimethyl-1,2-benzanthracene; D008715:Methionine; D020887:Selenious Acid; D012643:Selenium; D000518:Eflornithine